Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines.

Terziroli Beretta-Piccoli, Benedetta; Stirnimann, Guido; Mertens, Joachim; Semela, David; Zen, Yoh; Mazzucchelli, Luca; Voreck, Anja; Kolbus, Norbert; Merlo, Elisabetta; Di Bartolomeo, Claudia; Messina, Paola; Cerny, Andreas; Costantini, Silvia; Vergani, Diego; Mieli-Vergani, Giorgina (2021). Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines. Journal of autoimmunity, 116(102578), p. 102578. Elsevier 10.1016/j.jaut.2020.102578

Text 1-s2.0-S0896841120302110-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (3MB)

BACKGROUND & AIM

The diagnosis of primary biliary cholangitis (PBC), an uncommon immune-mediated cholestatic liver disease, is based on positive circulating anti-mitochondrial (AMA) and/or PBC-specific anti-nuclear autoantibodies (ANA), coupled with elevated serum alkaline phopsphatase (ALP) levels. Timely initiation of treatment with ursodeoxycholic acid prevents progression to cirrhosis and liver failure. We aimed at investigating liver histology in patients with normal ALP level and positive AMA and/or PBC-specific ANA.

METHODS

We searched the Swiss PBC Cohort Study database, which includes subjects with positive PBC autoimmune serology and normal ALP levels, for patients who underwent a liver biopsy. Histological slides were centrally reviewed by an expert liver pathologist, and sera were centrally re-tested for AMA and ANA.

RESULTS

30 patients were included; 90% females, median age 53 (range 27-72) years. Twenty-four (80%) had liver histology typical for (n = 2), consistent with (n = 16) or suggestive of (n = 6) PBC, including three of four AMA-negative ANA-positive patients. Among 22 ursodeoxycholic acid treated patients, 14 had elevated GGT levels before treatment; a significant decrease of the median GGT level between pre- (1.46 x ULN) and post- (0.43 x ULN) treatment (p = 0.0018) was observed.

CONCLUSIONS

In our series, a high proportion of AMA positive patients with normal ALP levels have PBC. For the first time we show histological diagnosis of PBC in AMA-negative/PBC-specific ANA-positive subjects and the potential role of GGT as a biomarker in PBC patients with normal baseline ALP levels. Current guidelines for the diagnosis of PBC do not cover the whole extent of PBC presentation, with important clinical implications in terms of timely treatment initiation.

Interest & Impact

Downloads

0 since deposited on 18 Dec 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item